Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiviral, peptides and glycopeptides | 5417 | 2012558-47-1 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Bulevirtide is an antiviral medicine used to treat chronic (long-term) hepatitis delta virus (HDV) infection in adults with compensated liver disease (when the liver is damaged but is still able to work), when the presence of viral RNA (genetic material) has been confirmed by blood tests. Bulevirtide blocks the entry of HBV and HDV into hepatocytes by binding to and inactivating NTCP, a bile salt liver transporter serving as essential HBV/HDV entry receptor.
|
| Dose | Unit | Route |
|---|---|---|
| 2 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 31, 2020 | EMA | MYR GmbH |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | J05AX28 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Other antivirals |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:64951 | anti-HBV agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chronic viral hepatitis B with hepatitis D | indication | 235869004 | |
| Chronic infection caused by Hepatitis D virus | indication | 735451005 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium/bile acid cotransporter | Transporter | INHIBITOR | IC50 | 6.49 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| D11877 | KEGG_DRUG |
| WKM56H3TLB | UNII |
| 406461-66-3 | SECONDARY_CAS_RN |
| C5139876 | UMLSCUI |
| CHEBI:757164 | CHEBI |
| CHEMBL4297711 | ChEMBL_ID |
| 134687648 | PUBCHEM_CID |
| DB15248 | DRUGBANK_ID |
| CHEMBL5315080 | ChEMBL_ID |
| CHEMBL4297792 | ChEMBL_ID |
| 10692 | INN_ID |
| C000718249 | MESH_SUPPLEMENTAL_RECORD_UI |
| C571888 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12775 | IUPHAR_LIGAND_ID |
| DB14853 | DRUGBANK_ID |
| 1025091000122104 | SNOMEDCT_US |
| 247311000202101 | SNOMEDCT_US |
| 019121 | NDDF |
| 2743603 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| HEPCLUDEX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61958-3104 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 8.50 mg | SUBCUTANEOUS | BLA | 33 sections |